Skip to main content


ACT now: anti-malarial market complexity one decade after the introduction of artemisinin combination therapy – evidence from sub-Saharan Africa and the Greater Mekong Sub-region

Since 2002, national malaria control programmes in sub-Saharan Africa (SSA) and the Greater Mekong Sub-region (GMS) responded to increasing resistance of Plasmodium to existing drugs by adopting artemisinin-based combination therapy (ACT) as first-line treatment. From 2012, countries have increasingly adopted recommendations by the World Health Organization to confirm all suspected malaria cases with diagnostic testing. In 2015, several countries in the GMS made bold steps towards malaria elimination, in the context of evidence of a resurgence in resistance to first-line treatments. In sub-Saharan Africa, efforts continue to rationalize malaria case management and further reduce prevalence of the disease.

ACTwatch has been monitoring anti-malarial and diagnostic markets since 2008. Standardized methods allow for comparability across survey rounds and over time, and provide evidence to inform policies, strategies and funding decisions. This series provides a comprehensive contemporary view of anti-malarial markets across several countries in SSA and the GMS, examining current levels of access to quality-assured first-line treatments and malaria diagnostics, and documenting the persistence of other non-first line medicines. This evidence serves as a benchmark for public and private sector initiatives that have aimed to scale up access to first-line treatment and confirmatory testing. Evidence can guide future strategies aimed at improving malaria case management and for accelerating progress towards malaria elimination.

ACTWatch have New Content Itempublished their datasets associated with this series. Links to individual dataset publications can be found within the 'Availability of data and materials' section of the articles below. You can also view the whole series of datasets here

  1. Research

    Testing times: trends in availability, price, and market share of malaria diagnostics in the public and private healthcare sector across eight sub-Saharan African countries from 2009 to 2015

    The World Health Organization guidelines have recommended that all cases of suspected malaria should receive a confirmatory test with microscopy or a malaria rapid diagnostic test (RDT), however evidence from ...

    Kara Hanson and Catherine Goodman

    Malaria Journal 2017 16:205

    Published on: 19 May 2017

  2. Research

    Private sector opportunities and threats to achieving malaria elimination in the Greater Mekong Subregion: results from malaria outlet surveys in Cambodia, the Lao PDR, Myanmar, and Thailand

    The aim of this paper is to review multi-country evidence of private sector adherence to national regulations, guidelines, and quality-assurance standards for malaria case management and to document current co...

    Sochea Phok, Saysana Phanalasy, Si Thu Thein and Asawin Likhitsup

    Malaria Journal 2017 16:180

    Published on: 2 May 2017

  3. Research

    The malaria testing and treatment landscape in Benin

    Since 2004, artemisinin-based combination therapy (ACT) has been the first-line treatment for uncomplicated malaria in Benin. In 2016, a medicine outlet survey was implemented to investigate the availability, ...

    Cyprien Zinsou and Adjibabi Bello Cherifath

    Malaria Journal 2017 16:174

    Published on: 26 April 2017

  4. Research

    What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism

    The private sector supplies anti-malarial treatment for large proportions of patients in sub-Saharan Africa. Following the large-scale piloting of the Affordable Medicines Facility-malaria (AMFm) from 2010 to ...

    Sarah Tougher, Kara Hanson and Catherine Goodman

    Malaria Journal 2017 16:173

    Published on: 25 April 2017